Projects & More
ITTM S.A. is partner in Smart4Health (www.smart4health.eu) a project of the European Union with the aim to realize a platform for electronic health records and far-reaching value-added services for EU citizens throughout Europe. This means that all EU citizens have their own health data, which can contain any diagnoses, treatments, medication plans and fitness data. Doctors and therapists can access data across institutional and national borders only with the consent of the citizen. The Smart4Health consortium consists of 18 partners from medical, social and technical sciences, and industry. Smart4Health is funded through the European Union's Horizon 2020 research and innovation programme under Grant Agreement No 826117 with a maximum of €21.8 million over 50 months.
ITTM S.S. is partner of the IMI TRANSLATIONAL SAFETY BIOMARKER PIPELINE PROJECT TO ENABLE DEVELOPMENT AND IMPLEMENTATION OF NOVEL SAFETY BIOMARKERS, a five-year program to generate exploratory and confirmatory data supporting regulatory qualification and acceptance of novel safety biomarkers for five target organ systems (kidney, liver, pancreas, vascular, and central nervous system) for application in drug development. The TransBioLine Project is a consortium of 27 partners across pharmaceutical companies, small and medium-sized enterprises, and academic institutions from 10 European countries, and is coordinated by the University of Zurich with Pfizer Inc. as the industry lead. It is funded by the IMI Joint Undertaking as a public-private partnership, with a budget of 28M€ and will be active through 2024.
ITTM S.A is partner in the GLIOTRAIN European Training Network (EU H2020/Marie Skłodowska-Curie Actions 766069). Its objective is to identify novel therapeutic strategies for application in Glioblastoma (GBM - the most frequent, aggressive and lethal of all brain tumours), while implementing state of the art next generation sequencing, systems medicine and integrative multi-omics to unravel disease resistance mechanisms. Research activities incorporate applied systems medicine, integrative multi-omics leveraging state of the art platform technologies, and translational cancer biology implementing the latest clinically relevant models. Read more
ITTM S.A. is a partner of the EU CHARME Cost Action (Harmonising standardisation strategies to increase efficiency and competitiveness of European life-science research CA 15110). The project aims to merge different approaches of research data standardization by connecting several efforts in the field of systems biology. By now there are many different approaches and solutions. CHARME wants to increase the awareness for the need of standards by enabling the reuse of research assets and making research more efficient and economical. Read more